teclistamab,hyaluronidase,pomalidomide,talquetamab,daratumumab
genmab,janssen
['trimm-2', 'darzalex,faspro', 'talquetamab', 'darzalex', 'multiple myeloma']
the phase ii trimm-2 study, presented at 2023, revealed promising outcomes in multiple myeloma-treated patients who underwent treatment with the experimental subcutaneous (sc) combination therapy of talquetamab + darzalex faspro. explore more: 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry